These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia. Stadtmauer EA Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767 [TBL] [Abstract][Full Text] [Related]
6. [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia]. Hirayama Y; Terui T; Koike K; Neda H; Ishitani K; Kohda K; Kuroda H; Iyama S; Sato T; Kobune M; Takimoto R; Kato J Rinsho Ketsueki; 2009 Aug; 50(8):663-5. PubMed ID: 19915382 [TBL] [Abstract][Full Text] [Related]
7. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine. Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270 [TBL] [Abstract][Full Text] [Related]
8. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Chowdhury S; Seropian S; Marks PW Am J Hematol; 2009 Sep; 84(9):599-600. PubMed ID: 19650144 [TBL] [Abstract][Full Text] [Related]
9. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association. Farhat H; Reman O; Raffoux E; Berthon C; Pautas C; Kammoun L; Chantepie S; Gardin C; Rousselot P; Chevret S; Dombret H; Castaigne S Am J Hematol; 2012 Jan; 87(1):62-5. PubMed ID: 22072535 [TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Specchia G; Pastore D; Carluccio P; Spinosa G; Giannoccaro M; Rizzi R; Mestice A; Liso V Ann Hematol; 2007 Jun; 86(6):425-8. PubMed ID: 17364181 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse. Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410 [TBL] [Abstract][Full Text] [Related]
12. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Stone RM; Moser B; Sanford B; Schulman P; Kolitz JE; Allen S; Stock W; Galinsky I; Vij R; Marcucci G; Hurd D; Larson RA; Leuk Res; 2011 Mar; 35(3):329-33. PubMed ID: 20688393 [TBL] [Abstract][Full Text] [Related]
13. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. Prebet T; Etienne A; Devillier R; Romeo E; Charbonnier A; D'incan E; Esterni B; Arnoulet C; Blaise D; Vey N Cancer; 2011 Mar; 117(5):974-81. PubMed ID: 20957721 [TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. Hütter-Krönke ML; Benner A; Döhner K; Krauter J; Weber D; Moessner M; Köhne CH; Horst HA; Schmidt-Wolf IG; Rummel M; Götze K; Koller E; Petzer AL; Salwender H; Fiedler W; Kirchen H; Haase D; Kremers S; Theobald M; Matzdorff AC; Ganser A; Döhner H; Schlenk RF Haematologica; 2016 Jul; 101(7):839-45. PubMed ID: 27036160 [TBL] [Abstract][Full Text] [Related]
15. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984 [TBL] [Abstract][Full Text] [Related]
16. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Wang ES; Zeidan A; Tan W; Wilding GE; Ford LA; Wallace PK; Hahn TE; Battiwalla M; McCarthy PL; Wetzler M Leuk Lymphoma; 2012 Oct; 53(10):2085-8. PubMed ID: 21740302 [No Abstract] [Full Text] [Related]
17. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Brethon B; Yakouben K; Oudot C; Boutard P; Bruno B; Jérome C; Nelken B; de Lumley L; Bertrand Y; Dalle JH; Chevret S; Leblanc T; Baruchel A Br J Haematol; 2008 Nov; 143(4):541-7. PubMed ID: 18759760 [TBL] [Abstract][Full Text] [Related]
18. Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. Lang K; Menzin J; Earle CC; Mallick R Am J Health Syst Pharm; 2002 May; 59(10):941-8. PubMed ID: 12040733 [TBL] [Abstract][Full Text] [Related]
19. [Gemtuzumab ozogamicin as monotherapy and combination therapy for acute myelogenous leukemia]. Usui N Rinsho Ketsueki; 2007 Jun; 48(6):458-67. PubMed ID: 17633093 [No Abstract] [Full Text] [Related]
20. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Apostolidou E; Cortes J; Tsimberidou A; Estey E; Kantarjian H; Giles FJ Leuk Res; 2003 Oct; 27(10):887-91. PubMed ID: 12860007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]